<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0010">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="lis0005">
   <list-item id="lsti0005">
    <label>•</label>
    <p id="par0005">IFN-I, in particular IFN-β, are promising drugs for SARS-CoV2 infection.</p>
   </list-item>
   <list-item id="lsti0010">
    <label>•</label>
    <p id="par0010">Early infection in elderly patients is the best setting to exploit IFN-I immunomodulatory activity.</p>
   </list-item>
   <list-item id="lsti0015">
    <label>•</label>
    <p id="par0015">Caution should be given in using continuous IFN-I treatments at high doses.</p>
   </list-item>
   <list-item id="lsti0020">
    <label>•</label>
    <p id="par0020">Mucosal IFN-I delivery is promising but deserves further clinical investigation.</p>
   </list-item>
   <list-item id="lsti0025">
    <label>•</label>
    <p id="par0025">Attention should be paid to IFN-I treatment in patients with severe COVID-19.</p>
   </list-item>
  </list>
 </p>
</abstract>
